01/12/21 8:30 AMNASDAQ : HJLIHancock Jaffe Concludes Successful VenoValve Pre-IDE Meeting with FDAHancock Jaffe Laboratories, Inc. (NASDAQ:HJLI), a developer of medical devices that restore cardiac and vascular health, today announced that it has successfully concluded itsRHEA-AIvery positive
12/30/20 4:15 PMNASDAQ : HJLIHancock Jaffe Announces Executive PromotionsHancock Jaffe Laboratories, Inc. (NASDAQ:HJLI), a developer of medical devices that restore cardiac and vascular health, today announced that Dr. Hamed Alavi has been promoted to Vice President of Research and Development and Quality and that CraigRHEA-AIneutral
12/21/20 8:30 AMNASDAQ : HJLIHancock Jaffe Deemed Compliant With All NASDAQ Continued Listing RequirementsHancock Jaffe Laboratories, Inc. (NASDAQ:HJLI), a developer of medical devices that restore cardiac and vascular health, today announced that the Company has received formal notificationRHEA-AIneutral
12/16/20 8:30 AMNASDAQ : HJLIHancock Jaffe Reports Two CoreoGraft Patients Have Reached 30 Day MilestoneHancock Jaffe Laboratories, Inc. (NASDAQ:HJLI), a developer of medical devices that restore cardiac and vascular health, today announced that two patients who have undergone heartRHEA-AIneutral
12/14/20 8:30 AMNASDAQ : HJLIHancock Jaffe Announces One Year Follow-up Data on Eleventh VenoValve PatientHancock Jaffe Laboratories, Inc. (NASDAQ:HJLI)(NASDAQ:HJLIW), a developer of medical devices that restore cardiac and vascular health, announced today that the eleventh andRHEA-AIpositive
12/10/20 8:30 AMNASDAQ : HJLIHancock Jaffe to Provide VenoValve and CoreoGraft Updates at Ladenburg Thalmann R&D Showcase Webinar on December 16, 2020Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI), a developer of medical devices that restore cardiac and vascular health, today announced that on Wednesday, December 16, 2020, at 1:00RHEA-AIneutral
12/01/20 8:30 AMNASDAQ : HJLI, HJLIWHancock Jaffe Announces One Year Follow-up Data on Tenth VenoValve PatientHancock Jaffe Laboratories, Inc. (NASDAQ:HJLI, HJLIW), a developer of medical devices that restore cardiac and vascular health, announced today that the tenth VenoValve patient in HJLI's first-in-human,RHEA-AIneutral
11/27/20 8:30 AMNASDAQ : HJLIHancock Jaffe Announces Reverse Stock SplitHancock Jaffe Laboratories, Inc. (NASDAQ:HJLI), a developer of medical devices that restore cardiac and vascular health, today announced that the company's Board of Directors has approved a reverse stock split of its shares of common stock at a ratio ofRHEA-AIneutral
11/23/20 8:30 AMNASDAQ : HJLIHancock Jaffe's VenoValve(R) Results Featured in Journal of Vascular Surgery Venous and Lymphatic DisordersHancock Jaffe Laboratories, Inc. (NASDAQ:HJLI), a developer of medical devices that restore cardiac and vascular health, today announced that the Journal of Vascular SurgeryRHEA-AIneutral
11/05/20 1:45 PMNASDAQ : HJLIHancock Jaffe Announces Date for VenoValve Pre-IDE Meeting with FDAHancock Jaffe Laboratories, Inc. (NASDAQ:HJLI), a developer of medical devices that restore cardiac and vascular health, today announced that the Pre-IDE meeting with the U.S. Food and Drug Administration ("FDA")RHEA-AIneutral
